GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nykode Therapeutics AS (STU:5VB) » Definitions » Price-to-Owner-Earnings

Nykode Therapeutics AS (STU:5VB) Price-to-Owner-Earnings : (As of May. 24, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Nykode Therapeutics AS Price-to-Owner-Earnings?

As of today (2025-05-24), Nykode Therapeutics AS's share price is €0.1937. Nykode Therapeutics AS does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Nykode Therapeutics AS's Price-to-Owner-Earnings or its related term are showing as below:


STU:5VB's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 28.53
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-05-24), Nykode Therapeutics AS's share price is €0.1937. Nykode Therapeutics AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.11. Therefore, Nykode Therapeutics AS's PE Ratio (TTM) for today is At Loss.

As of today (2025-05-24), Nykode Therapeutics AS's share price is €0.1937. Nykode Therapeutics AS's EPS without NRI for the trailing twelve months (TTM) ended in was €-0.11. Therefore, Nykode Therapeutics AS's PE Ratio without NRI for today is At Loss.

During the past 8 years, Nykode Therapeutics AS's highest PE Ratio without NRI was 20.05. The lowest was 0.00. And the median was 16.87.


Nykode Therapeutics AS Price-to-Owner-Earnings Historical Data

The historical data trend for Nykode Therapeutics AS's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nykode Therapeutics AS Price-to-Owner-Earnings Chart

Nykode Therapeutics AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

Nykode Therapeutics AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nykode Therapeutics AS's Price-to-Owner-Earnings

For the Biotechnology subindustry, Nykode Therapeutics AS's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nykode Therapeutics AS's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nykode Therapeutics AS's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Nykode Therapeutics AS's Price-to-Owner-Earnings falls into.


;
;

Nykode Therapeutics AS Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Nykode Therapeutics AS's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.1937/-0.10
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nykode Therapeutics AS  (STU:5VB) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Nykode Therapeutics AS Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Nykode Therapeutics AS's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Nykode Therapeutics AS Business Description

Traded in Other Exchanges
Address
Gaustadalleen 21, Oslo Research Park, Oslo, NOR, 0349
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need.

Nykode Therapeutics AS Headlines

No Headlines